Definium Therapeutics, Inc.

DFTX · NasdaqGS · Stock · Healthcare

$34.24

-0.41% today

Delayed price, 2026-10-14 20:16 UTC

What Definium Therapeutics does

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Key facts

Sector

Healthcare

Industry

Biotechnology

Market cap

$4.60B

P/E (ttm)

—

Forward P/E

-17.6

Dividend yield

0.00%

Beta

2.19

Profit margin

0.0%

Employees

105

Headquarters

New York, NY, United States

Exchange

NasdaqGS

Website

definiumtx.com

Performance

1 Month

-11.8%

3 Months

-22.7%

6 Months

+51.0%

1 Year

+150.8%

5 Years

+15.3%

$10.4752-week range$49.70

Biggest setback — last 12 months

-27.3%

6 Jul 2026 → 14 Oct 2026

Fell from $47.07 to $34.24 — its sharpest sustained decline this year.

Biggest run-up — last 12 months

+340.7%

17 Nov 2025 → 6 Jul 2026

Ran from $10.68 to $47.07 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Above long-term trend

Price sits above its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.

Horizon	Bear case (−1σ)	Base case	Bull case (+1σ)
1 Month	$28.34 (-17.2%)	$34.24	$41.37 (+20.8%)
3 Months	$24.68 (-27.9%)	$34.24	$47.51 (+38.7%)
6 Months	$21.55 (-37.1%)	$34.24	$54.41 (+58.9%)
12 Months	$17.79 (-48.1%)	$34.24	$65.92 (+92.5%)

Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 65.5%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Amneal Pharmaceuticals, Inc.

$18.90 · -3.4%

LGND

Ligand Pharmaceuticals Incorporated

$294.99 · -2.8%

MANE

Veradermics, Incorporated

$113.47 · -2.4%

INDV

Indivior Pharmaceuticals, Inc.

$34.16 · -3.6%

EWTX

Edgewise Therapeutics, Inc.

$37.02 · +2.0%

Recent headlines

Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results — Simply Wall St.Why Definium Therapeutics (DFTX) Is Up 5.7% After Second Positive Phase 3 DT120 Anxiety Trial Result — Simply Wall St.Definium Therapeutics (DFTX) After Its Phase 3 Win Still Looks Undervalued — Simply Wall St.DFTX Stock Climbs As High As 12% On ‘Unprecedented’ Anxiety Data For LSD-Based Drug — Stocktwits DFTX Stock Jumps Overnight As Investors Brace For Phase 3 Results From LSD-Based Anxiety Drug — Stocktwits Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus — Simply Wall St.

Recent insider activity

Acquired 1,086 shares at $35.52 — Vallone Carol A, Director · 2026-09-18

Acquired 1,629 shares at $35.52 — Krebs Andreas, Director · 2026-09-18

Acquired 200,000 shares — Karlin Daniel, Chief Medical Officer · 2026-09-14

Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

What is a stock? Understanding risk and reward Why diversification matters

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.